184 related articles for article (PubMed ID: 33306683)
1. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC
PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
4. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
6. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
7. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
[TBL] [Abstract][Full Text] [Related]
8. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
9. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
[TBL] [Abstract][Full Text] [Related]
10. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
13. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
14. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
16. miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs.
Zhang N; Li Y; Zheng Y; Zhang L; Pan Y; Yu J; Yang M
Lab Invest; 2019 Apr; 99(4):568-576. PubMed ID: 30552364
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.
Hsia TC; Liang JA; Li CC; Chien CR
Thorac Cancer; 2018 Nov; 9(11):1398-1405. PubMed ID: 30152040
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
Chen L; Fu M; Zhou J; Yao Y; Zhou J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
20. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
Bergqvist M; Christensen HN; Wiklund F; Bergström S
Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
